ISSN 2515-8260
 

Research Article 


Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning.

Abstract
Therapeutic targets for neurodegenerative conditions are constantly emerging. Diseases such as amyotrophic lateral sclerosis and Huntington׳s disease are multifactorial and involve dysfunction of various cellular pathways. Protein aggregate formation is one of the crucial pathological signs of cellular dysfunction, and is characteristic of many neurodegenerative conditions. Proteins recruited to these aggregates are thought to play a role in formation of the pathogenic inclusions. This review aims at exploring the current evidence for protein aggregation and the role for Arfaptin2, as a candidate factor contributing to the formation of aggresomes and a potential therapeutic target in motor neuron disease.

Focal points

Bedside

Understanding the multifactorial nature of the pathogenesis of neurodegenerative diseases will contribute to the research into the therapeutic targets of the disease, allowing more factors to be discovered in patients affected by the debilitating disorders of the nervous system.


Benchside

Collaborative efforts in investigating the causes and pathways of neurodegeneration are likely to increase the chance of discovering novel therapy approaches that may be utilised in more than one type of neurodegenerative disorders.


Industry

The application of the novel therapeutic target such as Arfaptin, and other proteins associated with protein aggregates, to the development of therapy approaches may open new avenues in drug discovery for neurodegenerative diseases.


Community

Diseases of central nervous system bear a great impact on the quality of life of the patients and their carers. Promoting the awareness through communicating the current state of the research provides a form of a mental support to those affected by these conditions.


Regulatory agencies

The need for funding the research into the basic understanding of the mechanisms involved in the pathogenesis of the neurodegenerative conditions must not be overlooked. The research into the cellular defects provides with invaluable findings about the healthy and diseased cell functioning.

Key words: Amyotrophic lateral sclerosisArfaptin2Huntington׳s diseaseMotor neuron diseaseNeurodegenerative diseaseProtein aggregationProtein degradationTherapeutic target


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Aida M. Mohammedeid
Articles by Vera Lukashchuk
Articles by Ke Ning
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. EJMCM. 2014; 2(1): 12-15.


Web Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. http://www.ejmcm.com/?mno=116527 [Access: September 14, 2020].


AMA (American Medical Association) Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. EJMCM. 2014; 2(1): 12-15.



Vancouver/ICMJE Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. EJMCM. (2014), [cited September 14, 2020]; 2(1): 12-15.



Harvard Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning (2014) Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. EJMCM, 2 (1), 12-15.



Turabian Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. 2014. Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. European Journal of Molecular & Clinical Medicine, 2 (1), 12-15.



Chicago Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. "Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases." European Journal of Molecular & Clinical Medicine 2 (2014), 12-15.



MLA (The Modern Language Association) Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning. "Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases." European Journal of Molecular & Clinical Medicine 2.1 (2014), 12-15. Print.



APA (American Psychological Association) Style

Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning (2014) Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases. European Journal of Molecular & Clinical Medicine, 2 (1), 12-15.





Most Viewed Articles
  • Predictive Value of Coronary CT Angiography and Calcium Scoring for Coronary Artery Problems and Adverse Cardiac Events in Low-risk Chest Pain Patients
    Aref Albakri, Giso Frhr.von der Recke, Heyder Omran
    EJMCM. 2020; 7(1): 01-04
    » Abstract

  • Genetic and Cell biology Discriminants of Sars-CoV2 Infection and Susceptibility to Covid-19 pulmonary complication
    P Scalia, SJ Williams, R Luca’, Antonio Giordano, E Bucci
    EJMCM. 2020; 7(1): 05-09
    » Abstract

  • Totally Extra-Peritoneal (TEP) laparoscopic ventral hernia and incisional hernia repair: Reverse TEP (r-TEP)
    Danilo Coco, Silvana
    EJMCM. 2019; 6(1): 12-13
    » Abstract

  • Protein aggregation and Arfaptin2: A novel therapeutic target against neurodegenerative diseases
    Aida M. Mohammedeid, Vera Lukashchuk, Ke Ning
    EJMCM. 2014; 2(1): 12-15
    » Abstract

  • Ease of Intubation While Using Macintosh and (Mccoy’s Type) Laryngoscope Blade Undergoing with Anaesthesiology
    N.V. Kanase, Saudamini Gandhi, Saurabh R Todi
    EJMCM. 2020; 7(1): 70-73
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.04

  • Most Downloaded
  • Serum Magnesium Level in Patients With Chronic Renal Failure
    Nitin N. Jadhav, Hardik Mahendra Kumar Patel
    EJMCM. 2020; 7(1): 80-85
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.06

  • Metabolic Syndrome and Framingham Risk Score in Coronary Artery Disease Cases
    Ganesh Shankarrao Thorat, Virendra C. Patil
    EJMCM. 2020; 7(1): 74-79
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.05

  • Effects of Infection with Toxoplasma Gondii to the Levels of Thyroid Hormones
    Taghreed Ahmed Mustafa Al-Issawi, Aysir Saleh Mohammed
    EJMCM. 2020; 7(1): 110-114
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.11

  • Immunohistochemical Expression of KI-67 in Ovarian Surface Epithelial Tumors and its Correlation
    Vohra Nikita Vinod, Sujata R. Kanetkar
    EJMCM. 2020; 7(1): 90-94
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.08

  • Statistical Analysis on Novel Corona Virus: COVID-19
    Vimal Kumar M N, JAYA R, Rubesh C M, Aakash Ram S
    EJMCM. 2020; 7(1): 95-103
    » Abstract » doi: https://doi.org/10.31838/ejmcm.07.01.09

  • Most Cited Articles